Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial

Table 1 Characteristics of patients with refractory germ cell tumors enrolled in the sutent phase 2 study and outcomes at presentation

Pt #	Race	Age ++	PS	Primary mass	Pathology- Components	Prior Therapies	AFP ng/ml (0–5.0)	B-HCG mIU/ml (0–1)	LDHIU/L (313–618)
1	AA	17	0	Testis	Seminoma;Embryonal, Choriocarcinoma, Immature teratoma, Mature teratoma.	R orchiectomy, BEP × 4, RPLND,TIP, Gem + Etoposide, Avastin + Gem, Avatin, Taxol, Gem,	18495.6	<1.0	2386
2	Asian	20	0	Mediastinum	Yolk sac tumor, Endodermal Sinus Tumor.	BEP × 3, TIP × 2, Surgery- multiple, ACE × 2	2087.9	<1.0	419
3	White	36	1	Testis	Embryonal Carcinoma (80%) and yolk sac tumor (20%)	R orchiectomy, BEP × 3, RPLND,TIP × 4, XRT- T10 -L2 , Cisplatin + Epirubicin × 4, XRT to R chest wall, WBRT, Oxaliplatin + Gem, × 4, Oxaliplatin × 8, Gem × 3, etoposide × 3	108.9	<1.1	524
4	White	19	1	Retro-peritoneal mass	Teratoma and Choriocarcinoma	BEP × 4, TIP × 1, VIP × 5, HD-SCT with carboplatin + etoposide, RPLND,	1.1	227865.8	794
5	White	29 and 52*	1	Testis	Embryonal Carcinoma (80%) and yolk sac tumor (20%)	R orchiectomy, 20 yrs later BEP × 3, EP × 1, RPLND, TIP × 2, ACE × 1	235.5	19.8	635

Abbreviations: ++Age Age at original diagnosis, PS Performance status, *Age at relapse, AA African American, R Right, BEP Bleiomycin, Etoposide, Cisplatin, RPLND Retroperitoneal Lymph node dissection, TIP Taxol, Ifosfamide, Cisplatin, VIP VP-16, Ifosfamide, Cisplatin, ACE Actinomycin, Cyclophosphamide, Etoposide. Gem Gemcitabine.

ISSN: 1756-8722